ArticleGynecologic oncology reports2025
Adenoid basal cell carcinoma: An underrecognized cervical malignancy.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adenoid basal cell carcinoma is a rare cervical malignancy which is indolent in nature but resembles more commonly occurring aggressive malignancies. Cases: Here we describe three cases of cervical adenoid basal cell carcinoma. All patients had a history of cervical dysplasia with high-risk HPV. The first and second patient were treated with hysterectomy, and the third patient opted for surveillance after cold knife conization. All patients have no evidence of disease to date. Conclusion: Cervical adenoid basal cell carcinoma is a rare malignancy that requires careful diagnostic attention due to its histologic similarities to more aggressive malignancies and the risk of misclassification. Advances in diagnostic criteria including immunohistochemistry (IHC) classification are key to distinguishing this unique pathological entity. Definitive treatment depends on accurate diagnosis. Optimal treatment involves surgical management with hysterectomy and lymph node assessment. Excisional biopsy with thorough pathologic evaluation for invasive carcinoma can be considered in patients who desire future fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.